PSMD8 Promotes Breast Cancer Progression and Attenuates Paclitaxel Sensitivity by Regulating the Expression of KIF10

Zhiyu Li,Chenyuan Li,Yi Tu,Feng Yao,Shengrong Sun,Shichong Liao,Zhong Wang

DOI: https://doi.org/10.21203/rs.3.rs-859898/v1

2021-01-01

Abstract:Abstract BackgroundBreast cancer (BC) patients were threatened by distant metastasis and drug resistance for a long time. The mechanism was to be explored urgently. Proteasome 26S subunit non-ATPase 8 (PSMD8) was associated with protein degradation, but little was known about its role in BC.MethodsThe bioinformatics analysis was obtained from public databases. Breast cancer cell lines were knocked down or overexpressed PSMD8/kinesin family member 10 (KIF10) and detected their ability of proliferation and invasion. epithelial-to-mesenchymal transition (EMT)-related markers were detected by the western blot and immunohistochemistry. In vivo models were established to verify the effect of PSMD8 on tumor growth and distant metastasis. Cells were exposed to paclitaxel (PTX) and examined their apoptosis by flow cytometry.ResultsIn the present study, we defined PSMD8 as a tumor-promoting molecule. PSMD8 was abnormally upregulated in BC tissues compared with adjacent tissues. High PSMD8 expression was related to poor prognosis in BC patients. The knockdown of PSMD8 attenuated the biological effect and epithelial-mesenchymal transition (EMT) progression in vitro and in vivo, and the overexpression of PSMD8 increased tumor progression in vitro. Furthermore, PSMD8 knockdown dramatically augmented the sensitivity of BC cells to paclitaxel, whereas PSMD8 overexpression showed the opposite effects. Mechanistic analysis indicated that PSMD8 activated the expression of kinesin family member 10 (KIF10) and its downstream extracellular regulated MAP kinase (ERK) signaling. Similar to PSMD8, we revealed that the expression of KIF10, which showed a positive correlation with PSMD8, was increased in BC tissues compared with adjacent tissues and associated with a poor prognosis of BC patients. The KIF10 knockdown significantly antagonized the facilitating effect of PSMD8 on the EMT program and chemotherapy tolerance. Finally, knocking down the level of KIF10 or inhibiting the ERK pathway in PSMD8-overexpressing cell lines partially blocked EMT progression and resistance against paclitaxel (PTX). ConclusionsIn conclusion, our results demonstrated that the PSMD8/KIF10 axis promoted BC development and PTX resistance via the ERK pathway. Our findings provide a theoretical basis for targeting PSMD8 to BC cells as a novel target for the treatment of BC.